Business
PRTC Presents at Two Upcoming Investor Conferences
PRTC Presents at Two Upcoming Investor Conferences.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n 17 November 2022\n \n \n PureTech Health plc\n \n \n \n \n \n PureTech to Present at Two Upcoming Investor Conferences\n \n \n \n \n \n PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that members of the management team will participate in fireside chats at two upcoming investor conferences. Webcasts of the presentations will be available at https://investors.puretechhealth.com.\n \n \n Piper Sandler 34th Annual Healthcare Conference\n \n \n Presenters: Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Finance and Operating Officer, and Julie Krop, M.D., Chief Medical Officer\n \n \n Date: Tuesday, November 29, 2022\n \n \n Time: 1:30 p.m. EST\n \n \n \n \n \n Evercore ISI 5th Annual HealthCONx Conference\n \n \n Presenter: Daphne Zohar, Founder and Chief Executive Officer, and Julie Krop, M.D., Chief Medical Officer\n \n Date: Wednesday, November 30, 2022\n \n \n Time: 8:50 a.m. EST\n \n \n \n \n About PureTech Health\n \n \n PureTech is a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third that will soon be filed for FDA approval, as of the date of PureTech's most recently filed Half-Year Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.\n \n For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.\n \n \n \n Cautionary Note Regarding Forward-Looking Statements\n \n \n This press release contains statements tha...